Clot-removal procedure for basilar artery blockage with a large stroke
Tests clot removal plus medical care against medical care alone in adults with basilar stroke.
Plain-language title generated from the registry record
Registry title: Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core
Key facts
- Where
- Hefei, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07672795, who can take part
Where in China
- The First Affiliated Hospital of USTCHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of University of Science and Technology of China
- Trial code
- NCT07672795
- Record updated
- 13 October 2026
- Original description
Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.Read full original descriptionShow less
Efficacy and Safety of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core: A Prospective, Multicenter, Randomized Controlled Trial
Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.
This prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS <7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.
Inclusion: Clinical presentation or imaging findings consistent with posterior-circulation ischemic stroke; Basilar artery occlusion confirmed by CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA); Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥10 before randomization; Age 18-85 years, inclusive; Baseline noncontrast CT, CTA source images, or diffusion-weighted MRI (DWI) demonstrating at least one of the following:; Posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) of 0-5; or; Pons-Midbrain Index (PMI) >4; Randomization within 24 hours of the estimated time of basilar artery occlusion; The estimated time of basilar artery occlusion is defined as the sudden onset of stroke symptoms consistent with acute basilar artery occlusion; For patients with wake-up stroke or an unknown time of symptom onset, the last known well (LKW) time will be used as the reference time; randomization must occur within 24 hours of LKW; Written informed consent provided by the participant or their legally authorized representative.
Exclusion: Allergy to contrast agents or nickel-titanium alloy; A documented history of cerebral vasculitis; A pre-existing neurological or psychiatric disorder that would interfere with clinical assessment; Imaging-Based Exclusion Criteria; Intracranial hemorrhage on CT or MRI. Patients with cerebral microbleeds <5 mm in diameter detected on MRI may be included; A hereditary or acquired bleeding diathesis, coagulation factor deficiency, or oral anticoagulant use with an international normalized ratio (INR) >3.0; Blood glucose <50 mg/dL (2.8 mmol/L) or >400 mg/dL (22.2 mmol/L), platelet count <50 × 10⁹/L, or hematocrit <25%; Prestroke modified Rankin Scale (mRS) score ≥3; Pregnancy or breastfeeding; Current participation in another clinical trial; Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg that cannot be controlled with antihypertensive treatment; Life expectancy <1 year; Inability to complete the 90-day follow-up, for example because of a lack of a fixed residence or residence overseas that prevents follow-up; Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that would make endovascular treatment technically difficult; An intracranial tumor, except for a small meningioma.